Registered under Taiwan pharmaceutical license: TFDA Permit No. 011653. Approved as an over-the-counter hydrogel medicated patch for topical application.
Manufactured by TEH SENG Pharmaceutical Mfg. Co., Ltd., located at No. 42, Huan Gong Road, Yong-Kang District, Tainan City, Taiwan. The company specializes in advanced transdermal drug delivery systems including hydrogel, oil-based, and hot-melt patches, operating under CGMP / PIC/S GMP standards.
This product (Jin Si Gao Sip"T.S.") is a high-tech product developed under a science and technology project commissioned by the Ministry of Economic Affairs from 1997 to 1999, and has undergone product safety and energetically evaluations conducted by the Department of Pharmacy of Chia Nan University of Pharmacy and Science in 1990.
Product verification:After each batch of products is produced, the company's QA unit personnel are responsible for sampling, and the QC unit personnel are responsible for testing. Only after the quality assurance department supervisor determines that the products are qualified can they be released.
Raw material contro
Process control
Finished Product Control
Incoming Materials: Raw material supplier evaluation, raw material inspection
In-process Control: In-process control
Finished Products: Finished product inspection
Post-market Management: Customer complaint system, defective product recall mechanism, regular inspections by regulatory authorities
Establish standard operating procedures (SOPs) for drug safety monitoring programs, risk management, and CAPA System.
This product is manufactured under Teh Seng Pharmaceutical’s proprietary production license and represents an advanced hydrogel-based transdermal patch technology. The formulation is protected under the company chairman’s Republic of China invention patent, titled “Hydrophilic Transdermal Absorption Preparation” (Invention Patent No. I227145). In addition, the product incorporates further technological enhancements developed by Teh Seng’s R&D team, leading to the acquisition of a second Republic of China patent for its improved release liner design, titled “Improved Backing Film for Medicated Patches” (Utility Model No. M253362). These patents reflect the company’s continued commitment to innovation in transdermal delivery systems and the development of high-performance hydrogel patches.
